Cash, Cash Equivalents and Restricted Cash [USD, thousands]

Accounts Receivable [USD, thousands]

Available-for-Sale Securities, at Fair Value [USD, thousands]

Prepaid Expenses [USD, thousands]

Other Current Assets [USD, thousands]

Total Current Assets [USD, thousands]

Property, Plant and Equipment, Net [USD, thousands]

Intangible Assets, Net [USD, thousands]

Right-of-Use Assets [USD, thousands]

Other Assets [USD, thousands]

Total Assets [USD, thousands]

Accounts Payable [USD, thousands]

Accrued Expenses [USD, thousands]

Accrued Payroll and Benefits [USD, thousands]

Lease Liabilities, Current Portion [USD, thousands]

Credit Facility, Current Portion [USD, thousands]

Total Current Liabilities [USD, thousands]

Lease Liabilities, Net of Current Portion [USD, thousands]

Liability Related to the Sale of Future Royalties [USD, thousands]

Credit Facility, Net of Current Portion [USD, thousands]

Total Long-Term Liabilities [USD, thousands]

Additional Paid-in Capital [USD, thousands]

Accumulated Other Comprehensive Income (Loss) [USD, thousands]

Accumulated Deficit [USD, thousands]

Total Arrowhead Pharmaceuticals, Inc. Stockholders’ Equity [USD, thousands]

Noncontrolling Interest [USD, thousands]

Total Noncontrolling Interest and Stockholders’ Equity [USD, thousands]

Total Liabilities, Noncontrolling Interest and Stockholders’ Equity [USD, thousands]

47057e9d859bcdf1f55e93f69f5f45f0739ebc44f18853439b83d3037f5eda45

Revenue (USD, thousands)

Research and Development Expenses (USD, thousands)

General and Administrative Expenses (USD, thousands)

Total Operating Expenses (USD, thousands)

Operating Loss (USD, thousands)

Interest Income (USD, thousands)

Interest Expense (USD, thousands)

Other, Net (USD, thousands)

Total Other Expense (USD, thousands)

Loss Before Income Tax Expense and Noncontrolling Interest (USD, thousands)

Income Tax Expense (Benefit) (USD, thousands)

Net Loss Including Noncontrolling Interest (USD, thousands)

Net Loss Attributable to Noncontrolling Interest, Net of Tax (USD, thousands)

Net Loss Attributable to Arrowhead Pharmaceuticals, Inc. (USD, thousands)

Basic Net Loss Per Share Attributable to Arrowhead Pharmaceuticals, Inc. (USD)

Diluted Net Loss Per Share Attributable to Arrowhead Pharmaceuticals, Inc. (USD)

Weighted-average Shares Used in Calculating Basic Net Loss Per Share (thousands)

Weighted-average Shares Used in Calculating Diluted Net Loss Per Share (thousands)

Unrealized (Losses) Gains on Available-for-Sale Securities (USD, thousands)

Foreign Currency Translation Adjustments (USD, thousands)

Comprehensive Loss (USD, thousands)

Total Other Income (Expense) (USD, thousands)

Operating (Loss) Income (USD, thousands)

(Loss) Income Before Income Tax (Benefit) Expense and Noncontrolling Interest (USD, thousands)

Net (Loss) Income Including Noncontrolling Interest (USD, thousands)

Net (Loss) Income Attributable to Arrowhead Pharmaceuticals, Inc. (USD, thousands)

Basic Net (Loss) Income Per Share Attributable to Arrowhead Pharmaceuticals, Inc. (USD)

Diluted Net (Loss) Income Per Share Attributable to Arrowhead Pharmaceuticals, Inc. (USD)

Comprehensive (Loss) Income (USD, thousands)

Change in Unrealized Losses on Available-for-Sale Securities (USD, thousands)

Amortization (Accretion) of Note Premiums/Discounts (USD, thousands)

Realized Loss on Investments (USD, thousands)

Non-cash Interest Expense on Liability Related to the Sale of Future Royalties (USD, thousands)

Other (USD, thousands)

Stock-based Compensation (USD, thousands)

Depreciation and Amortization (USD, thousands)

Realized Gain on Investments (USD, thousands)

e863bf3630dd7f655c6fcb10802e6ef4fa46d0e4158ba58d37b9b829f0392653

Net Loss (USD, thousands)

Stock-Based Compensation (USD, thousands)

Accretion of Note Premiums/Discounts (USD, thousands)

Non-Cash Interest Expense on Liability Related to Sale of Future Royalties (USD, thousands)

Non-Cash Interest Expense on Credit Facility (USD, thousands)

Other Operating Activities (USD, thousands)

Net Cash Used in Operating Activities (USD, thousands)

Purchases of Property and Equipment (USD, thousands)

Purchases of Investments (USD, thousands)

Proceeds from Sales and Maturities of Investments (USD, thousands)

Net Cash Provided by Investing Activities (USD, thousands)

Proceeds from the Exercises of Stock Options (USD, thousands)

Proceeds from Issuance of Pre-Funded Warrants (USD, thousands)

Proceeds from the Issuance of Common Stock, Net of Offering Costs (USD, thousands)

Proceeds from the Sale of Future Royalties (USD, thousands)

Proceeds from Credit Facility (USD, thousands)

Payment of Debt Issuance Costs (USD, thousands)

Net Cash Provided by Financing Activities (USD, thousands)

Net Decrease / (Increase) in Cash, Cash Equivalents and Restricted Cash (USD, thousands)

Effect of Exchange Rate on Cash, Cash Equivalents and Restricted Cash (USD, thousands)

Income Taxes Paid (USD, thousands)

Capital Expenditures Included in Accrued Expenses (USD, thousands)

Debt Issuance Costs Included in Accrued Expenses (USD, thousands)

Accounts Receivable (USD, thousands)

Prepaid Expenses and Other Assets (USD, thousands)

Accounts Payable (USD, thousands)

Accrued Expenses (USD, thousands)

Deferred Revenue (USD, thousands)

Operating Lease, Net (USD, thousands)

Cash, Cash Equivalents and Restricted Cash, Beginning of Period (USD, thousands)

Cash, Cash Equivalents and Restricted Cash, End of Period (USD, thousands)

be7006032c3cda4610b11e34cf45f9c1f21395fc6655e8b04197594561d30d1b

Number of patients dosed in a Phase 2 trial for daplusiran/tomligisiran (patients)

Dose dependent reductions in circulating CFB protein for ARO-CFB with greater than 3 months duration (percentage)

40261a9d9bafb3f5a3fe58db4b953508848adb5806f558ce25a571cdc95ba4b3

- Milestone Payment

Horizon

Takeda

Janssen

Amgen

Total Revenue

761e196c3c1cd8aa8372b28547754ef2548b31e25bdc3e70b147d39102553691

ARROWHEAD PHARMACEUTICALS (ARWR)

Financials